Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
Indications↗
Distinct diseases across all programs
Clinical Trials↗
All sponsored trials (all statuses)
Pipeline
By Phase
3 drugs in development
By Therapeutic Area
top 1
R&D Momentum
88/100
Pipeline Velocity
67/100
Trial Completion Rate
92/100
Pipeline Concentration
56/100
Pipeline Freshness
61/100
Strategic Signals
Activity
Last 14 days
Resistance Exercise Training to Preserve Muscle Mass and Physical Function During Incretin-Based Weight Loss
Infant Food Allergen Oral Immunotherapy (InFO)
Identifying Parents in Child Welfare Services Who Need Mental Health Support: Depression and Anxiety Symptoms and Associated Factors
National Highly Specialized Care (NHV) for Children and Adolescents With Severe Self-Harm and Eating Disorders: Evaluation of Treatment Experiences, Feasibility, and Clinical Outcomes
A Feasibility Study of the Collaboration-Screening-Referral Model - An Approach to Identify Parents in Child Welfare Services Who Need Mental Health Support
Assessing Tai Chi Based Rehabilitation to Improve Physical and Mental Health of Persons With Multiple Sclerosis.
National Highly Specialized Care for Children With Severe Treatment-Refractory Self-Harm and Eating Disorders: Mapping, Development, and Evaluation - Substudy 3, Evaluation of Specialist Supportive Clinical Management (SSCM) for Children and Adolescents With Anorexia Nervosa and Atypical Anorexia Nervosa
Suicide Preventive Psychosocial Treatment for Youths: A Randomized Controlled Trial
Walking and Thinking - Brain Activity During Complex Walking in Atypical Parkinsonian Syndromes
Investigation of Loneliness and Its Associations With Emotion Regulation, Lifestyle Habits, Mental Health Problems, and Psychotherapeutic Treatment Outcomes, Substudy 5: Compassion-Focused Therapy (CFT) for Depression and Anxiety Disorders
National Highly Specialized Care (NHV) for Adults With Treatment-Resistant Self-Harm and Eating Disorders: Assessment, Development, and Evaluation - Substudy 1: Investigation of Patients' and Their Significant Others' Experiences of National Highly Specialized Care (NHV), Feasibility and Preliminary Treatment Outcomes
Details
Company Overview
—
Mkt Cap
—
Revenue
—
Cash
Pipeline
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)